Skip to main content

Cellular Genomics Platform

Using intersecting technologies to discover how individual cells impact our greatest health challenges

3D purple cell image

We use cellular genomic technologies to address critical medical research questions. Our Platform is one of the few global sites where state-of-the-art technologies are seamlessly integrated, including the latest platforms in flow cytometry, microfluidics, genomics, spatially-resolved transcriptomics, high-performance computing and bioinformatics.

Cellular genomics is the study of the genetic makeup of a single cell – a revolutionary technology that’s transforming biological and medical research. Generating genomic or proteomic information from a single cell within a spatial context, in large quantities and quickly, reveals the cellular mechanisms and interactions that lead to disease. Using this information, we can develop early-stage screening and diagnostic methods, identify the best treatment options for individual patients and develop therapies that target disease-causing cells.

To realise the potential of cellular genomics, our Platform brings together several intersecting technologies under two main branches:

  • A production core with cutting-edge services in flow cytometry, single cell capture, spatial transcriptomics, sequencing and bioinformatics.
  • A research and development team evaluating and implementing  the latest methods and approaches in molecular, spatial, sequencing and computational areas of cellular genomics.

We offer services to support all your flow cytometry and single cell genomics research needs. The flow core provides flow cytometry services for analysing and sorting cells, as well as training and expert consultation for experiment planning. We are equipped with three cell sorters, five analysers, one autoMACS and three data analysis stations.

The molecular core provides state-of-the-art expert services across a variety of single cell capture and spatial imaging platforms, encompassing capture, molecular processing, sequencing, and preliminary data analysis of samples.


Flow cytometry and Cellular Genomics Services

Supporting internal and external researchers with expert services in flow cytometry, cellular genomics and spatial profiling

Flow cytometry and Cellular Genomics Services

Supporting internal and external researchers with expert services in flow cytometry, cellular genomics and spatial profiling

Find out more

Since 2017, the Cellular Genomics Platform has embarked on a range of research programs, both nationally and internationally. Under the broader themes of immune profiling, stem-cell modelling and cancer clone therapeutics, researchers are using cellular genomics to study the genetic risk of disease across cell development stages, find ‘cancer causing’ cells in tumour environments and identify the genetic variants that may cause immune disease.

Our current collaborative research programs include:

    • Cancer Cell Therapeutics: supporting the development of new drugs that are cancer cell specific, as well as creating clinical management strategies that allow clinicians to identify cancer patients’ cell-types.
    • HOPE Research: using cellular genomics to identify the ‘rogue cells’ that cause autoimmune disease and develop new therapies that target these cells.
    • OneK1K: a pioneering study that is demonstrating how genetics contribute to the risk of immune disease at a cellular level, by analysing 1,000 cells from 1,000 people.
    • Stem cells: In collaboration with leading stem cell scientists across Australia and the UK, the Platform is using single-cell sequencing and advanced machine learning to investigate how the genetic risk of disease varies across cell development stages.
    • Prediabetes: working towards developing algorithms that predict a prediabetic individual’s response to treatment, by conducting a major study that evaluates patient responses to different therapies.
    • Melanoma: developing tools for predicting how melanomas will respond to treatment, to tailor immunotherapies to individual patients and tumours, by performing whole genome sequencing and RNA sequencing on melanoma samples from the tumour bank.